Thymidylate synthase inhibitors - Pipeline Insight, 2024

Thymidylate synthase inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Thymidylate synthase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Thymidylate synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Thymidylate synthase inhibitors Understanding

Thymidylate synthase inhibitors: Overview

Thymidylate synthetase is an important enzyme, which is responsible for the reductive methylation of deoxyuridylic acid (dUMP) to deoxythymidylic acid (dTMP). The methylation of the uracil moiety (present in RNA) to 5-methyl uracil (thymine, present in DNA) requires participation of a folic acid coenzyme, N5, N10-methylenetetrahydrofolate as a methyl donor. Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy.[1] This inhibition prevents the methylation of C5 of deoxyuridine monophosphate (dUMP) thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP).

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Thymidylate synthase inhibitors R&D. The therapies under development are focused on novel approaches for Thymidylate synthase inhibitors.

Thymidylate synthase inhibitors Emerging Drugs Chapters

This segment of the Thymidylate synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thymidylate synthase inhibitors Emerging Drugs

• ADX 2191: Aldeyra Therapeutics

ADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR). The observed clinical activity of ADX-2191 in patients with PVR is believed to be the result of down-regulation of aberrant retinal cell proliferation and activity, thereby leading to reduced retinal scarring that is characteristic of PVR. Aldeyra retains an exclusive license to certain patents related to the use of ADX-2191 for the prevention of PVR.

• LY-01616: Luye Pharma

LY01616 is an innovative combinational liposome formulation loaded with irinotecan and floxurudine, indicated for the treatment of advanced colorectal cancer. LY01616 was independently developed by Luye Pharma through its Laboratory for Long-acting and Targeting Drug Delivery Systems.

Further product details are provided in the report……..

Thymidylate synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Thymidylate synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Thymidylate synthase inhibitors

There are approx. 18+ key companies which are developing the Thymidylate synthase inhibitors. The companies which have their Thymidylate synthase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Aldeyra Therapeutics.

• Phases

DelveInsight’s report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Thymidylate synthase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thymidylate synthase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Thymidylate synthase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thymidylate synthase inhibitors drugs.

Thymidylate synthase inhibitors Report Insights

• Thymidylate synthase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Thymidylate synthase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Thymidylate synthase inhibitors drugs?
• How many Thymidylate synthase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thymidylate synthase inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thymidylate synthase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Thymidylate synthase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aldeyra Therapeutics
• Luye Pharma Group
• Nucana BioMed
• Roche
• ROS Therapeutics
• Nordic Group
• Taiho Pharmaceutical
• Fivephusion
• Isofol Medical
• Eli Lilly and Company
• Nucana BioMed
• Mebiopharm
• Atlanthera
• SetLance
• Cardiol Therapeutics
• Venus Remedies
• Lumosa Therapeutics
• Celator Pharmaceuticals
• Sanofi

Key Products

• ADX 2191
• LY01616
• Fosifloxuridine nafalbenamide
• Capecitabine
• SAR-439281
• NUC 3373
• MBP Y003
• CTX02
• VRT 002 P
• CPX-1
• LT 2003
• Research programme - neurotensin conjugated anticancer therapies
• 1102-39
• Methotrexate prodrug
• Nordimet
• Pemetrexed
• SP-05
• TS-1
• LV/5-FU